Andere talen Personalis, Inc.

Aandelen

PSNL

US71535D1063

Geschatte realtime Cboe BZX Andere beurzen 17:01:26 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,515 ^USD	+11,40%		+10,88%	-27,14%

26/03	Personalis, Inc. Kondigt publicatie aan die de Next Personal-test valideert voor ultragevoelige MRD-detectie en bewaking van de respons op kankerbehandeling	CI
29/02	PERSONALIS, INC. : Needham & Co. bevestigt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Personalis to Announce First Quarter 2024 Financial Results	24/04
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference	28/03
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting	28/03
Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring	27/03
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	20/03
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/03
Personalis: Q4 Earnings Snapshot	28/02
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M	28/02
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results	28/02
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	28/02
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results	14/02
Personalis to Participate at Upcoming Investor Conferences	31/01
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	30/01
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology	30/01
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	30/01
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	18/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Personalis, Inc.

Aandelen

PSNL

US71535D1063

Andere talen

Filters